UK markets close in 5 hours 36 minutes

Immix Biopharma, Inc. (IMMX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.5000-0.0700 (-2.72%)
At close: 04:00PM EDT
2.6201 +0.12 (+4.80%)
After hours: 07:42PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 65.99M
Enterprise value 46.98M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.02
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.02

Trading information

Stock price history

Beta (5Y monthly) 0.05
52-week change 332.98%
S&P500 52-week change 321.61%
52-week high 37.7500
52-week low 31.4000
50-day moving average 33.0196
200-day moving average 33.5290

Share statistics

Avg vol (3-month) 3286.41k
Avg vol (10-day) 3176.57k
Shares outstanding 526.4M
Implied shares outstanding 626.4M
Float 814.09M
% held by insiders 145.91%
% held by institutions 18.47%
Shares short (28 Mar 2024) 4388.84k
Short ratio (28 Mar 2024) 41.86
Short % of float (28 Mar 2024) 42.09%
Short % of shares outstanding (28 Mar 2024) 41.52%
Shares short (prior month 29 Feb 2024) 4264.07k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-57.92%
Return on equity (ttm)-106.23%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -16.14M
Net income avi to common (ttm)-15.43M
Diluted EPS (ttm)-0.8900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)17.51M
Total cash per share (mrq)0.66
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.32
Book value per share (mrq)0.82

Cash flow statement

Operating cash flow (ttm)-11.37M
Levered free cash flow (ttm)-5.94M